Aspen Neuroscience, Inc. (NASDAQ:ASPE – Get Free Report) Director Peter Thompson acquired 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was purchased at an average price of $15.00 per share, with a total value of $15,000,000.00. Following the completion of the acquisition, the director owned 3,589,132 shares in the company, valued at $53,836,980. The trade was a 38.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Aspen Neuroscience Price Performance
NASDAQ:ASPE opened at $12.76 on Thursday. Aspen Neuroscience, Inc. has a 12 month low of $11.20 and a 12 month high of $14.90.
About Aspen Neuroscience
Aspen Neuroscience, Inc is a biotechnology company focused on developing regenerative medicine therapies for neurological disorders. The company’s approach uses a patient’s own cells to create induced pluripotent stem cells, which are then differentiated into specialized cells intended to replace damaged or lost tissue.
Aspen’s lead program, ANPD001, is designed as a potential cell replacement therapy for Parkinson’s disease. The company has also developed genetic screening and manufacturing processes intended to evaluate a patient’s cells and produce an individualized therapeutic product.
Aspen Neuroscience is headquartered in San Diego, California.
Featured Stories
- Five stocks we like better than Aspen Neuroscience
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Aspen Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
